← Leaderboards
Brian L Schmidt
New York University
$17,732,867
Attributed
$38,976,600
Total exposure
19
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9.4M · FY2006–25$10M$7.5M$5M$2.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$38,976,600 · 19
By mechanism
R01$28,961,290 · 11
RM1$4,820,611 · 1
UG3$3,174,343 · 1
R21$1,260,402 · 3
R56$396,250 · 1
R34$303,470 · 1
Top collaborators
- Donna G Albertson17 shared
- Nigel W Bunnett17 shared
- Seiichi Yamano10 shared
- Markus Hardt7 shared
- Igor Spigelman6 shared
- Catherine M Cahill1 shared
- Rajesh Khanna1 shared
- Kam W Leong1 shared
Most similar at New York University
Same institution · by research overlap
- Nigel W Bunnett$19,331,815
- Kathleen W. Kinnally$3,340,003
- Yi Ye$8,884,555
- Yatendra Mulpuri$162,743
Others in their field
Top investigators on “Pain”
- Emer Leahy · Psychogenics, Inc.$49,781,254
- Lynn Larson Debar · Kaiser Foundation Research Institute$37,527,482
- J Richard Landis · University Of Pennsylvania$34,799,488
- Clifford J Woolf · Boston Children'S Hospital$30,992,766
- Emeran A Mayer · University Of California Los Angeles$29,229,798
- Pamela Susan Douglas · Duke University$28,862,172
Research focus
PainNociceptionCancer PainMalignant NeoplasmsMalignant Mouth NeoplasmCancer PatientMouse ModelClinical TrialsSignal TransductionOpioidAgonistNeuronsNociceptorsOralBaseCell LineSide EffectTumor MicroenvironmentAfferent NeuronsInnovationPathway InteractionsMediatingReceptorQuality Of Life
Grant awards (66)
TRPV1 nociceptors in oral carcinogenesis and pain$615,159
R01 · FY2025 · CA
Intratumor co-delivery of DNA and RNA to relieve cancer pain$583,847
R01 · FY2025 · DE · contact PI
Endosomal Platforms for Signaling Pain$563,958
R01 · FY2025 · NS
Targeting Endosomal Receptors for Treatment of Chronic Pain$795,324
R01 · FY2024 · DE
Endosomal Platforms for Signaling Pain$647,474
R01 · FY2024 · NS
TRPV1 nociceptors in oral carcinogenesis and pain$596,271
R01 · FY2024 · CA
Intratumor co-delivery of DNA and RNA to relieve cancer pain$567,884
R01 · FY2024 · DE · contact PI
Artemin overexpression in oral cancer pain and carcinogenesis$306,247
R01 · FY2024 · CA
Endosomal mechanisms signaling oral cancer pain$4,820,611
RM1 · FY2023 · DE · contact PI
Peripherally-restricted non-addictive cannabinoids for cancer pain treatment$3,174,343
UG3 · FY2023 · NS
TRPV1 nociceptors in oral carcinogenesis and pain$605,687
R01 · FY2023 · CA
Intratumor co-delivery of DNA and RNA to relieve cancer pain$583,847
R01 · FY2023 · DE · contact PI
Artemin overexpression in oral cancer pain and carcinogenesis$202,375
R01 · FY2023 · CA
Protease/PAR2/TRPV4 Axis and Oral Cancer Pain$707,316
R01 · FY2022 · DE · contact PI
TRPV1 nociceptors in oral carcinogenesis and pain$627,398
R01 · FY2022 · CA
Intratumor co-delivery of DNA and RNA to relieve cancer pain$573,679
R01 · FY2022 · DE · contact PI
Artemin overexpression in oral cancer pain and carcinogenesis$536,258
R01 · FY2022 · CA
Targeting Endosomal Receptors for Treatment of Chronic Pain$319,147
R01 · FY2022 · DE
Trafficking-Dependent Signaling of Pain by Protease-Activated Receptors$872,508
R01 · FY2021 · DK
Protease/PAR2/TRPV4 Axis and Oral Cancer Pain$725,228
R01 · FY2021 · DE · contact PI
TRPV1 nociceptors in oral carcinogenesis and pain$625,751
R01 · FY2021 · CA
Intratumor co-delivery of DNA and RNA to relieve cancer pain$583,847
R01 · FY2021 · DE · contact PI
Artemin overexpression in oral cancer pain and carcinogenesis$490,586
R01 · FY2021 · CA
Targeting Endosomal Receptors for Treatment of Chronic Pain$222,945
R01 · FY2021 · DE
Targeting Endosomal Receptors for Treatment of Chronic Pain$3,385,528
R01 · FY2020 · DE
Trafficking-Dependent Signaling of Pain by Protease-Activated Receptors$880,716
R01 · FY2020 · DK
Protease/PAR2/TRPV4 Axis and Oral Cancer Pain$731,251
R01 · FY2020 · DE · contact PI
Artemin overexpression in oral cancer pain and carcinogenesis$520,500
R01 · FY2020 · CA
Peripherally-restricted cannabinoids for cancer and chemotherapy-induced pain$441,204
R01 · FY2020 · CA · contact PI
Protease/PAR2/TRPV4 Axis and Oral Cancer Pain$741,363
R01 · FY2019 · DE · contact PI
Trafficking-Dependent Signaling of Pain by Protease-Activated Receptors$695,955
R01 · FY2019 · DK
Artemin overexpression in oral cancer pain and carcinogenesis$495,216
R01 · FY2019 · CA
Peripherally-restricted cannabinoids for cancer and chemotherapy-induced pain$474,187
R01 · FY2019 · CA · contact PI
Protease/PAR2/TRPV4 Axis and Oral Cancer Pain$241,425
R01 · FY2019 · DE · contact PI
Protease/PAR2/TRPV4 Axis and Oral Cancer Pain$770,424
R01 · FY2018 · DE · contact PI
Trafficking-Dependent Signaling of Pain by Protease-Activated Receptors$708,358
R01 · FY2018 · DK
Peripherally-restricted cannabinoids for cancer and chemotherapy-induced pain$492,705
R01 · FY2018 · CA · contact PI
Non-viral gene therapy for cancer pain$397,065
R01 · FY2018 · DE · contact PI
Genome amplification and dysbiosis in tongue cancer$237,750
R21 · FY2018 · DE
Peripherally-restricted cannabinoids for cancer and chemotherapy-induced pain$587,089
R01 · FY2017 · CA · contact PI
Non-viral gene therapy for cancer pain$401,629
R01 · FY2017 · DE · contact PI
Genome amplification and dysbiosis in tongue cancer$198,125
R21 · FY2017 · DE
Non-viral gene therapy for cancer pain$111,367
R01 · FY2017 · DE · contact PI
Peripherally-restricted cannabinoids for cancer and chemotherapy-induced pain$559,935
R01 · FY2016 · CA · contact PI
Non-viral gene therapy for cancer pain$407,053
R01 · FY2016 · DE · contact PI
Non-viral gene therapy for cancer pain.$396,250
R56 · FY2015 · DE · contact PI
The Role of Proteases and Peptides in Cancer Pain$439,458
R01 · FY2014 · DE · contact PI
The Role of Proteases and Peptides in Cancer Pain$461,531
R01 · FY2013 · DE · contact PI
A DNA biomarker of oral cancer metastasis$303,470
R34 · FY2013 · DE · contact PI
FISH assay identifying oral cancer patients at low risk of lymph node metastasis$179,778
R21 · FY2013 · CA
FISH assay identifying oral cancer patients at low risk of lymph node metastasis$8,027
R21 · FY2013 · CA
The Role of Proteases and Peptides in Cancer Pain$439,458
R01 · FY2012 · DE · contact PI
FISH assay identifying oral cancer patients at low risk of lymph node metastasis$215,021
R21 · FY2012 · CA
The Role of Proteases and Peptides in Cancer Pain$42,375
R01 · FY2012 · DE · contact PI
The Role of Proteases and Peptides in Cancer Pain$550,454
R01 · FY2011 · DE · contact PI
The Role of Proteases and Peptides in Cancer Pain$370,740
R01 · FY2011 · DE · contact PI
The Role of Proteases and Peptides in Cancer Pain$457,397
R01 · FY2010 · DE · contact PI
A Novel Gnawing Assay to Quantify Nociception in Models of Chronic Orofacial Pain$229,201
R21 · FY2008 · DE · contact PI
Predictive Markers for Oral Carcinoma Metastasis$218,077
R01 · FY2008 · CA · contact PI
Predictive Markers for Oral Carcinoma Metastasis$48,208
R01 · FY2008 · CA · contact PI
Predictive Markers for Oral Carcinoma Metastasis$265,423
R01 · FY2007 · CA · contact PI
A Novel Gnawing Assay to Quantify Nociception in Models of Chronic Orofacial Pain$192,500
R21 · FY2007 · DE · contact PI
Predictive Markers for Oral Carcinoma Metastasis$272,463
R01 · FY2006 · CA · contact PI
INTRODUCTORY PHASE$0
K16 · FY2002 · DE
INTRODUCTORY PHASE$0
K16 · FY2001 · DE
INTRODUCTORY PHASE$60,234
K16 · FY2000 · DE